PATENT CLAIM ANALYSIS

Application Number: 15885936
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "186100"]

Abstract:
A personalized method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus, by determining a nucleic acid sequence of the proviral DNA harbored by a subject, designing two or more different guide RNAs (gRNAs) complementary to the proviral DNA sequences in the subject, treating the subject's host cells with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of the proviral DNA, and inactivating the proviral DNA.

Claim (Index 6):
The method of  claim 1 , wherein the CRISPR-associated endonuclease is Cas9 or a human-optimized Cas9.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 88.0
- Lexical Diversity: 1.92424
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14838057', '15148261', '14951240', '15864715', '15430218']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7322040677828524
- 35 USC 102 Novelty (BERT): 0.6514342011764699
- Combined Prediction Score: 0.7241270811222141
- Mean Citation Score: 450.57792599999993
- Max Citation Score: 645.8347
- Similarity Product: 594.4000966029762

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test